ISIN | AT0000A1FNT0 |
---|---|
Valor Number | 28871817 |
Bloomberg Global ID | |
Fund Name | DSC Equity Fund – Healthcare A|A |
Fund Provider |
Dreyfus Söhne & Cie AG, Banquiers
Aeschenvorstadt 16 | Postfach 4051 Basel Schweiz Phone: +41 61 286 66 66 Web: https://www.dreyfusbank.ch |
Fund Provider | Dreyfus Söhne & Cie AG, Banquiers |
Representative in Switzerland |
Dreyfus Söhne & Cie AG, Banquiers Basel |
Distributor(s) |
Dreyfus Söhne & Cie AG, Banquiers Basel |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Distribution |
Home Country | Austria |
Issuing Condition | The fund does not charge any issuing commission and/or fees (units are issued at the NAV) |
Redemption Condition | The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV) |
Investment Strategy *** | N/A |
Peculiarities |
Current Price * | 232.19 CHF | 08.11.2024 |
---|---|---|
Previous Price * | 232.20 CHF | 07.11.2024 |
52 Week High * | 246.77 CHF | 03.09.2024 |
52 Week Low * | 204.64 CHF | 10.11.2023 |
NAV * | 232.19 CHF | 08.11.2024 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 41,387,253 | |
Unit/Share Assets *** | 37,314,735 | |
Trading Information SIX |
YTD Performance | +10.64% |
29.12.2023 - 08.11.2024
29.12.2023 08.11.2024 |
---|---|---|
1 month | -1.42% |
08.10.2024 - 08.11.2024
08.10.2024 08.11.2024 |
3 months | -0.13% |
08.08.2024 - 08.11.2024
08.08.2024 08.11.2024 |
6 months | -1.66% |
08.05.2024 - 08.11.2024
08.05.2024 08.11.2024 |
1 year | +11.57% |
08.11.2023 - 08.11.2024
08.11.2023 08.11.2024 |
2 years | -0.62% |
08.11.2022 - 08.11.2024
08.11.2022 08.11.2024 |
3 years | -3.82% |
08.11.2021 - 08.11.2024
08.11.2021 08.11.2024 |
5 years | +14.93% |
08.11.2019 - 08.11.2024
08.11.2019 08.11.2024 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Eli Lilly and Co | 6.67% | |
---|---|---|
Johnson & Johnson | 5.95% | |
UnitedHealth Group Inc | 5.81% | |
Novo Nordisk AS Class B | 4.53% | |
Merck & Co Inc | 4.48% | |
Abbott Laboratories | 4.03% | |
Regeneron Pharmaceuticals Inc | 3.85% | |
AbbVie Inc | 3.69% | |
Amgen Inc | 3.33% | |
Sanofi SA | 3.13% | |
Last data update | 30.09.2024 |
TER | 1.53% |
---|---|
TER date | 30.04.2024 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 1.50% |
Ongoing Charges *** | 1.53% |
SRRI ***
|
|
SRRI date *** | 31.10.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |